Metabolic syndrome and worksite health promotion

American Journal of Health Promotion

Volumn 21, Issue 1, 2006, Pages 1-11

  Leutzinger, Joseph ^a   Pirner, Mark ^a   Landschulz, William ^b   Nevins, Richard Lewis ^c   Sullivan, Sean ^c   Silberman, Cheryl ^c  

^a Abbott Nutrition International   (United States)

^b Metabolic and Renal Disease Development

^c SSS Audit Team   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; DYSLIPIDEMIA; HEALTH CARE COST; HEALTH PROMOTION; HUMAN; LIFESTYLE; METABOLIC SYNDROME X; OBESITY; OCCUPATIONAL HEALTH SERVICE; PRODUCTIVITY; WORKPLACE;

EID: 33748472379     PISSN: 08901171     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245-1250.
2. Aldana SG, Pronk NP. Health promotion programs, modifiable health risks, and employee absenteeism. J Occup Environ Med. 2001;43(1):36-46.
3. Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med. 2004;46(4):398-412.
4. Wright DW, Beard MJ, Edington DW. Association of health risks with the cost of time away from work. J Occup Environ Med. 2002;44(12):1126-1134.
5. Colditz GA. Economic costs of obesity and inactivity. Med Sci Sports Exerc. 1999;31(11 Suppl):S663-S667.
6. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications and its comorbidities. Med Care. 2001;39(6):599-615.
7. Killilea T. Long-term consequences of Type 2 diabetes mellitus: economic impact on society and managed care. Am J Manag Care. 2002;8(16 Suppl):S441-S449.
8. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res. 1998;6(2):97-106.
9. National Institutes of Health, Third report of the National Cholesterol Education Program Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. Bethesda, MD, National Institutes of Health, National Heart, Lung and Blood Institute, 2001 (NIH publ. No. 01-3670).
10. Alebiosu CO, Odusan BO. Metabolic syndrome in subjects with type-2 diabetes mellitus. J Natl Med Assoc. 2004;96(6):817-821.
11. Lorenzo C, Okoloise M, Williams K, et ai. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care. 2003;26(11):3153-3159.
12. Leutzinger J, Sullivan S, Chapman L. Platinum book: Practical applications of the health and productivity management model. USA: Institute for Health and Productivity Management. 2004.
13. Pelletier K. A review and analysis of the health and cost-effective outcomes studies of comprehensive health promotion and disease prevention programs. Am J Health Promo. 1991;5:311-315.
14. Pelletier K. A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs at the worksite: 1991-1993 update. Am J Health Promo. 1993;8:43-49.
15. Chapman LS. Health and productivity management framework and metrics. Platinum book: Practical applications of the health and productivity management model. USA: Institute for Health and Productivity Management. 2004.
16. Borden S. Five key insights into HPM. Platinum book: Practical applications of the health, and productivity management model. USA: institute for Health and Productivity Management. 2004.
17. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
19. Park Y-W, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Int Med. 2003;163(4):427-436.
20. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care, 2004;27(10):2444-2449.
21. Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis study. Diabetes Care. 2004;27(3):788-793.
22. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237-252.
23. Hanley AJ, Karter AJ, Festa A, et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51(8):2642-2647.
24. Cruz ML, Weigensberg MJ, Huang TTK, et al. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocinol Metab. 2004;89(1):108-113.
25. Crundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89(6):2595-2600.
26. Laaksonen DE, Lakka HM, Salonen JT, et al. Low levels of leisure time physical activity and cardiorespirarory fitness predict development of the metabolic syndrome. Diabetes Care. 2002;25(9):1612-1618.
27. Han TS, William K, Satter N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res. 2002;10(9):923-931.
28. Liese AD, Mayer-Davis E, Tryoler HA, et al. Development of multiple metabolic syndrome in the ARIC Cohort: joint contribution of insulin, BMI and WHR. Ann Epidemiol. 1997;7(6):407-416.
29. Okosun IS, Liao Y, Rotimi CN, et al. Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic Americans. Ann Epidemiol. 2000;10(5):263-270.
30. Rantala AO, Kauma H, Lilja M. et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med. 1999;245(2):163-174.
31. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004;89(6):2522-2525.
32. Eisenstein EL, Shaw LL, Nelson CL, et al. Obesity and long-term clinical and economic outcomes in coronary artery disease patients. Obes Res. 2002;10(2):83-91.
33. Oster G, Edelsberg J, O'Sullivan AK, Thompson D. The clinical and economic burden of obesity in a managed care setting. Am J Managed Care. 2000;6(6):681-689.
34. Thompson D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med. 1999;159(18):2177-2183.
35. Daviglus ML, Liu K, Yan LL, et al. Relation of Body Mass Index in young adulthood and middle age to Medicare expenditures in older age. JAMA. 2004;292(22):2743-2749.
36. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583-2589.
37. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from Type 2 diabetes in the U.S. Diabetes Care. 2002;25(3):476-481.
38. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Int Med. 1999;159(16):1873-1880.
39. Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand. 2000;78:374-385.
40. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The role of health risk factors and disease on worker productivity. J Occup Environ Med. 1999;41(10):863-877.
41. Hemp P. Presenteeism: at work-but out of it. Harvard Bus. Rev. 2004;82(10):49-58.
42. Schultz AB, Lu C, Barnett TE, et al. Influence of participation in a worksite health promotion program on disability days. J Occup Environ Med. 2002;44(8):776-780.
43. Musich S, Napier D, Edington DW. The association of health risks with workers' compensation costs. J Occup Environ Med, 2001;43(6):534-541.
44. American Diabetes Association. Diabetes and retinopathy (eye complications). http://www.diabetes.org/diabetes statistics/eye-complications. jsp. Website accessed February 2005.
45. Bertera RL. The effects of behavioral risks on absenteeism and health-care costs in the workplace. J Occ Med. 1991;33(11):1119-1124.
46. Boles M, Pelletier B, Lynch W. The relationship between health risks and work productivity. J Occup Environ Med. 2004;46(7):737-745.
47. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195-1200.
48. Ganz M. The economic evaluation of obesity interventions: its time has come. Obes Res. 2003;11(11):1275-1277.
49. Thompson D, Edelsberg J, Kinsey KL, et al. Estimated economic costs of obesity to U.S. Business. Am J Hlth Promot. 1998;13(2):120-127.
50. Lakdawalla DN, Bhattacharya J, Goldman DP. Are the young becoming more disabled? Hlth Aff. 2004;23(1):168-176.
51. National Center for Health Statistics. Summary health statistics for U.S. adults: National Health Interview Survey, 2002: Data from the National Health Interview Survey. July 2004.
52. Lean ME, Han TS, Seidell JC. Impairment of health and quality of life using new US federal guidelines for the identification of obesity. Arch Intern Med. 1999;159(8):837-843.
53. Hertz RP, Unger AN, McDonald M, et al. The impact of obesity on work limitations and cardiovascular risk factors in the U.S. workforce. J Occup Environ Med. 2004;46(12):1196-1203.
54. Kiiskinen U, Vartianinen E, Puska P, et al. Long-term cost and life-expectancy consequences of hypertension. J Hypertens. 1998;16(8):1103-1112.
55. Lynch W, Mercer WM, Riedel JE, et al. Measuring employee productivity: a guide to self-assessment tools. USA: Institute for Health and Productivity Management. 2001.
56. Prasad M, Wahlquist P, Shikiar R, Shih YCT. A review of self-report instruments measuring health-related work productivity. Pharmacoeconomics. 2004;22(4):225-244.
57. Allen HM Jr., Bunn WB 3rd. Using self-report and adverse event measures to track health's impact on productivity in known groups. J Occup Environ Med. 2003;45(9):973-983.
58. Goetzel RZ, Ozminkowski RJ, Long SR, Development and reliability analysis of the Work Productivity Short Inventory (WPSI) instrument measuring employee health and productivity. J Occup Environ Med. 2003;45(7):743-762.
59. Koopman C, Pelletier KR, Murray JF, et al. Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med. 2002;44(1):14-20.
60. Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;142(7):525-531.
61. Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;142(7):525-531.
62. Hyatt J. Future of obesity and chronic disease management in health care: the HMO perspective. Obes Res. 2002;10(suppl 1):79S-81S.
63. Walters G. Future of obesity and chronic disease management in health care: the employer perspective. Oies Res. 2002;10(Suppl 1):84S-86S.
64. Anderssen SA, Hjermann I, Urdal P, et al. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the "atherothrombogenic syndrome." Oslo Diet and Exercise Study (ODES). A randomized trial. J Intern Med. 1996;240(4):203-209.
65. Case CC, Jones PH, Nelson K, et al. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002;4(6):407-414.
66. Christ M, Iannello C, Iannello PG, et al. Effects of a weight reduction program with and without aerobic exercise in metabolic syndrome. Int J Cardiol. 2004;97(1):115-122.
67. Chapman LS. Reducing obesity in work organizations. Am J Health Promot. 2004;19(1):1-8.
68. Greenway FL, Ryan DH, Bray GA, et al. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res. 1999;7(6):523-531.
69. Hill JO, Bessesen D. What to do about metabolic syndrome? Arch Intern Med. 2003;163(4):395-397.
70. Wadden TA, Berkowitz RI, Sarwer DB, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med. 2001;161(2):218-227.
71. Wadden TA. Randomized trial of lifestyle modification and pharmaeotherapy for obesity. The New Engl J Med. 2005;353(20):2111-2120.
72. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):S32-546.
73. Hanif MW, Kumar S. Pharmacological management of obesity. Expert Opin Pharmacother. 2002;3(12):1711-1718.
74. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-1737.
75. Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142(7):547-559.
76. Irwin ML, Ainsworth BE, Mayer-Davis EJ, et al. Physical activity and the metabolic syndrome in a tri-ethnic sample of women. Obes Res. 2002;10(10):1030-1037.
77. Katzmarzyk PT, Church TS, Janssen I, et al. Metabolic Syndrome, obesity, and mortality: Impact of cardiorespiratory fitness. Diabetes Care. 2005;28(2):391-397.
78. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
79. Appel LJ, Moore FJ, Obarzanek E, et al. A Clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117-24.
80. Pescatello LS, Franklin BA, Fagard R, et al. American College of Sports Medicine position stand. Exercise and hypertension. Med Sci Sports Exerc. 2004;36(3):533-553.
81. Stone NJ. Focus on lifestyle change and the metabolic syndrome. Endocrinol Metab Clin North Am. 2004;33(3):493-508.
82. Damci T, Tatliagac S, Osar Z, Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Euro J Int Med. 2003;14(6):357-360.
83. Hanna B, Sander R, Dorothea C, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med. 1999;341(6):410-418.
84. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9B):25F-29F.
85. Jacobson TA, Case CC, Roberts S, et al. Characteristics of US Adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004;6(5):353-62.
86. Braunstein A, Li Y, Hirschland D, McDonald T, Edington DW. Internal associations among health-risk factors and risk prevalence. Am J Hlth Behav. 2001;25(4);407-417.
87. Prochaska JO. Treating entire populations for behavior risks for chronic diseases. Homeostasis in Hlth Dis. 2003;42(1-2):1-12.
88. Wang P, Beck A, Berglund P, et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med. 2003;45(12):1303-1311.
89. Burton WN, Conti DJ. Disability management: corporate medical department management of employee health and productivity. J Occup Environ Med. 2000;42(10):1006-1012.
90. Goetzel R, Ozminkowski R, Sederer L, Mark T. The business case for quality mental health services: why employers should care about the mental health and well-being of their employees. J Occup Environ Med. 2002;44:320-330.
91. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med. 2001;43(1);64-71.
92. Bernacki EJ, Guidera J, Schaefer JA, Tsai S. A facilitated early return to work program at a large urban medical center. J Occup Environ Med. 2000;42(12):1172-1177.
93. Burton WN, Conti DJ. Disability management: corporate medical department management of employee health and productivity. J Occup Environ Med. 2000;42(10):1006-1012.